US FDA approves Neurocrine Biosciences' genetic disorder drug
13/12/2024 22:45
Dec 13 (Reuters) - The U.S. Food and Drug Administration has approved Neurocrine Biosciences' NBIX.O drug to treat a type of genetic disorder, the health regulator's website showed on Friday. (Reporting by Sriparna Roy in Bengaluru; Editing by Alan Barona) ((Sriparna.Roy@thomsonreuters.com))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall